# GLORIOSA (NCT05445778)

> Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05445778
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
- Interventions: Mirvetuximab soravtansine plus Bevacizumab; Bevacizumab
- Enrollment: 520
- Primary outcome: Assess Progression-free survival (PFS)

## Commentary we found

- YouTube: 41
- Podcasts: 33

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=gloriosa-nct05445778

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05445778", "email": "<work email>"}; the inbox owner confirms by the emailed link.